drugset / Trial / NCT03645876
SHR-1210 in Combination With BP102 and XELOX in Patient With Metastatic Colorectal Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is an open label, single-arm, multi-center, phase II study of SHR-1210 in metastatic colorectal cancer patients with the recurrent lesion(s) post-surgery or the untreated mCRC. SHR-1210 is a humanized monoclonal antibody against Programmed death 1(PD-1).BP102 is a humanized recombinant monoclonal IgG1 antibody. The primary objective of this study is to investigate the safety and efficacy of the subjects who given the combination therapy.
Timeline
- Start
- 2018-11-08
- Primary completion
- 2019-04-18
- Completion
- 2019-04-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BP102 | Monoclonal antibody | 7.5 mg/kg | Intravenous |
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Capecitabine | Small molecule | 1000 mg/m2 | Oral |
| Subject | Oxaliplatin | Small molecule | 130 mg/m2 | Intravenous |